ODN 2216

1 Cited Publications
고객리뷰

Based on 1 publication(s) in Google Scholar

ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4+ T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4+ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8+ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • Purity: 98.57%
  • CAS No.: 332437-00-0
  • 분자량:6432.00
  • 보관:

    -20°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Biological Activity
  • Chemical Information
  • 순도&문서
  • References
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) ODN 2216

More

All Toll-like Receptor (TLR) Isoforms

More
100 mg
견적 받기 해외재고보유
Please select quantity
Price: USD 0.00